Efficacy of the NOA® mandibular advancement device in the management of obstructive sleep apnea: A cohort study

Objectives: To evaluate the efficacy, compliance, and side effects of the NOA® device compared to other mandibular advancement devices (MADs) in managing obstructive sleep apnea (OSA). Methods: Thirty-three participants using the NOA® device were evaluated based on apnea–hypopnea index (AHI) reduction (criterion I: >50% reduction of AHI or criterion II: residual AHI < 5 events/hour), compliance, temporomandibular disorders (TMDs), and patient-reported side effects. These data were compared to retrospective data of 59 patients receiving a different MAD. Results: Results showed that the NOA® device was effective in 78.8% (criterion 1) and 90.9% (criterion 2) of cases, requiring less mandibular advancement than other MADs. Participants used the device for an average of 6.94 ± 0.97 hours per night. Significant improvements were noted in morning headaches, sleep bruxism, and nocturnal urination. Conclusions: The NOA® device demonstrated high efficacy, improved patient-reported outcomes, and caused no significant side effects or issues. It required less mandibular advancement than other devices and had high patient compliance.